Actively Recruiting
Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Led by Taichung Veterans General Hospital · Updated on 2025-05-11
120
Participants Needed
1
Research Sites
399 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and a significant public health issue. MASLD may progress to liver cirrhosis and/or hepatocellular carcinoma. Although previous evidence suggests that aspirin has antisteatotic and antifibrotic effects on the liver, a randomized controlled trial assessing long-term efficacy and safety of aspirin in MASLD patients has yet to be conducted. This study aims to conduct a randomized controlled trial to evaluate the efficacy of aspirin in treating MASLD.
CONDITIONS
Official Title
Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with MASLD according to Delphi consensus with at least one of five cardiometabolic criteria
You will not qualify if you...
- Consuming alcohol at an average of 20 g/day or more for women, or 30 g/day or more for men
- HbA1c level 9.0% or higher
- Other chronic liver diseases such as hepatitis B or C, autoimmune hepatitis, Wilson's disease
- Liver decompensation classified as Child-Pugh class B or C
- Liver cirrhosis with significant portal hypertension (low platelet count, enlarged spleen, or varices)
- High-risk esophageal or gastric varices diagnosed by endoscopy within 6 months before screening
- Active peptic ulcer disease diagnosed by endoscopy within 6 months before screening
- FIB-4 index less than 1.3 at screening
- Indication for any anti-platelet therapy due to cardiovascular history
- History of aspirin allergy
- History of bleeding disorders such as hemophilia
- Pregnancy or breastfeeding
- Severe kidney impairment with eGFR less than 30 mL/min/1.73 m²
- Any malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Taichung Veterans General Hospital
Taichung, Taiwan, Taiwan, 40705
Actively Recruiting
Research Team
T
Teng-Yu Lee, MD, MBA, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here